biotech / news / / Barchart
Amgen Inc. (AMGN) has underperformed the broader market over the past year.
AMGN shares outperformed the Invesco Pharmaceuticals ETF YTD, despite lagging it over the past year.
KEY POINTS
- AMGN’s Q4 adjusted EPS of $5.29 and $9.9 billion revenue both exceeded Wall Street forecasts.
- AMGN’s analyst consensus has become less bullish, with fewer 'Strong Buy' ratings than three months ago.
- Canaccord Genuity recently initiated AMGN at 'Hold' with a $366 price target, implying 8.3% upside.
COMPANIES
Summarized by Newsio from Barchart. How we summarize →